Results 71 to 80 of about 910,008 (206)

Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

Scientific Reports, 2023
NTRK gene fusions are rare somatic mutations found across cancer types with promising targeted therapies emerging. Healthcare systems face significant challenges in integrating these treatments, with uncertainty in prevalence and optimal testing methods ...
Sophie O’Haire, Fanny Franchini, Yoon-Jung Kang, Julia Steinberg, Karen Canfell, Jayesh Desai, Stephen Fox, Maarten IJzerman   +7 more
doaj   +1 more source

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Frontiers in Oncology, 2022
Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors.
Chiara Lazzari, Lorenza Pecciarini, Claudio Doglioni, Federica Pedica, Ana Maria Samanes Gajate, Alessandra Bulotta, Vanesa Gregorc, Maria Giulia Cangi   +7 more
doaj   +1 more source

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance

Respirology Case Reports, 2022
Acquired resistance to osimertinib is inevitable and heterogeneous despite its documented efficacy against EGFR‐mutated non‐small cell lung cancer (NSCLC).
Jiao‐Li Wang, Liu‐sheng Wang, Jun‐qi Zhu, Jie Ren, Di Wang, Man Luo   +5 more
doaj   +1 more source

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC

JTO Clinical and Research Reports, 2023
Introduction: Gene fusion testing of ALK, ROS1, RET, NTRK, and MET exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC).
Véronique Hofman, MD, PhD, Simon Heeke, PhD, Christophe Bontoux, MD, Lara Chalabreysse, MD, Marc Barritault, MD, PhD, Pierre Paul Bringuier, DVM, Tanguy Fenouil, MD, PhD, Nazim Benzerdjeb, MD, PhD, Hugues Begueret, MD, PhD, Jean Philippe Merlio, MD, PhD, Charline Caumont, MD, Nicolas Piton, MD, PhD, Jean-Christophe Sabourin, MD, PhD, Solène Evrard, MD, PhD, Charlotte Syrykh, MD, Anna Vigier, MD, Pierre Brousset, MD, PhD, Julien Mazieres, MD, PhD, Elodie Long-Mira, MD, PhD, Jonathan Benzaquen, MD, PhD, Jacques Boutros, MD, Maryline Allegra, PhD, Virginie Tanga, MSc, Virginie Lespinet-Fabre, PhD, Myriam Salah, MSc, Christelle Bonnetaud, MSc, Olivier Bordone, MSc, Sandra Lassalle, MD, PhD, Charles-Hugo Marquette, MD, PhD, Marius Ilié, MD, PhD, Paul Hofman, MD, PhD   +30 more
doaj   +1 more source

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib. [PDF]

Mol Oncol, 2022
Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer.
Dziadziuszko R, Hung T, Wang K, Choeurng V, Drilon A, Doebele RC, Barlesi F, Wu C, Dennis L, Skoletsky J, Woodhouse R, Li M, Chang CW, Simmons B, Riehl T, Wilson TR.   +15 more
europepmc   +2 more sources

How I treat NTRK gene fusion-positive cancers [PDF]

ESMO Open, 2019
NTRK fusions are found at low frequencies (commonly
openaire   +4 more sources

MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. [PDF]

, 2019
Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of
Petrek, Hannah, Yu, Ai-Ming
core   +1 more source

Anterior Olfactory Nucleus [PDF]

, 2008
This report contains a gene expression summary of the anterior olfactory nucleus (AON), derived from the Allen Brain Atlas (ABA) in situ hybridization mouse data set.
Allen Institute for Brain Science, Angela L. Guillozet-Bongaarts, Beth M. Solan, Lydia L. Ng   +3 more
core   +2 more sources

Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours [PDF]

, 2021
Fusions de gens; Oncologia molecular; NeoplàsiaFusiones de genes; Oncología molecular; NeoplasiaGene fusions; Molecular oncology; NeoplasmThe recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the ...
Bautista, F., de Álava, E., Garrido, P., Hladun Alvaro, Raquel, López‑Ríos, F., Álvarez, R.   +5 more
core   +1 more source

Oncogenic fusions: Targeting NTRK

Critical Reviews in Oncology/Hematology
Non-Small Cell Lung Cancer (NSCLC) is responsible for the highest number of cancer-related deaths in the United States. Thankfully, advancements in the detection and targeting of gene mutations have greatly improved outcomes for many patients. One significant mutation driving oncogenesis in various cancers, including NSCLC, is the neurotrophic tyrosine
Garo Hagopian, Misako Nagasaka
openaire   +2 more sources